Retatrutide Dosage: A Beginner's Guide to Amounts and Ramping

Built by medical professionals, gym rats, and experienced biohackers

Retatrutide is a weekly injectable peptide that acts on three metabolic receptors at once. Research doses in published trials started at 1 mg per week and escalated gradually over several months. For beginners, the core rule is simple: start low, hold each dose long enough to adapt, and only move up when your body is ready.

What Is Retatrutide and How Is It Different?

Retatrutide is a triple agonist, meaning it targets GLP-1, GIP, and glucagon receptors at the same time. GLP-1 and GIP agonism reduce appetite and support blood sugar regulation. The added glucagon component is thought to increase energy expenditure, which sets retatrutide apart from dual agonists like tirzepatide.

It is still investigational and not FDA-approved as of mid-2026. Human data exists from Phase 2 trials, but long-term safety data is more limited than for older compounds in the same class.

What Doses Were Used in Research?

The Phase 2 trial published in the New England Journal of Medicine tested weekly subcutaneous doses of 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg. Participants started at 1 mg per week. Doses were increased on a set schedule, with several weeks held at each level before stepping up.

At 48 weeks, participants on higher doses saw significantly more weight change than those on lower doses. The 12 mg group showed the largest average reduction. These are research observations, not personal targets.

What Does a Typical Ramp Look Like?

Ramping means starting at the lowest dose and increasing slowly over weeks or months. Clinical trial protocols and community practice both follow a step-up structure:

Start: 1 mg per week for the first several weeks
Hold: Stay at each dose for at least 4 weeks before considering an increase
Increase: Move up only if side effects are well tolerated at the current level
Ceiling: The trial escalated up to 12 mg, but many people stabilize at lower doses

There is no single ramp that works for every person. The goal is finding the lowest dose that produces the effect you are looking for, then staying there.

Why Does Slow Ramping Matter So Much?

Retatrutide activates glucagon receptors in addition to GLP-1 and GIP. That combination can produce stronger nausea and GI effects early on, especially if doses increase too fast.

Holding each dose for at least 4 weeks gives the body time to adjust before adding more stimulus. Jumping doses too quickly is the most common beginner mistake reported in both clinical and community settings. Slower ramps are also linked to better long-term adherence in the GLP-1 class broadly.

How Do You Calculate the Right Amount to Inject?

Retatrutide comes as a lyophilized powder and must be reconstituted with bacteriostatic water before use. The dose you actually inject depends on how much water you added to the vial, so the math matters more than most people realize.

For example, if you add 2 mL of water to a 5 mg vial, you get a concentration of 2.5 mg per mL, or 0.25 mg per 0.1 mL drawn. Getting this wrong by even a small margin changes your actual dose meaningfully.

DoseVault handles the reconstitution math for you. Enter your vial size and water volume, and it returns the exact units to draw. Logging each dose also gives you a clean record of where you are in your ramp week by week.

What Side Effects Should Beginners Expect?

The most common side effects in the Phase 2 trial were nausea, vomiting, diarrhea, and decreased appetite. These were most common during the first few weeks at each new dose level.

Most participants reported that GI effects faded with time. Side effects were more frequent and more intense at higher doses. If side effects are significant, holding the current dose rather than continuing to escalate is the standard approach in both research and community practice.

Is Retatrutide Stronger Than Semaglutide or Tirzepatide?

Based on Phase 2 data, retatrutide produced larger average weight changes than were seen in comparable trials of semaglutide and tirzepatide. The triple-receptor mechanism is believed to be responsible.

That also means the side effect profile can be more intense early on, especially at higher doses. Stronger output does not always mean better if tolerability becomes a problem.

FAQ

Is retatrutide FDA approved?
No. As of mid-2026, retatrutide remains investigational. It is available through research-only channels and compounding pharmacies in some regions.

How often is retatrutide injected?
Once per week, subcutaneously.

Can I start at a higher dose to see results faster?
Research and community experience both point to starting at 1 mg regardless of prior experience with other peptides. The triple-receptor mechanism can produce more intense early side effects than single or dual agonists.

What happens if I miss a dose?
General guidance for weekly peptides is to take the missed dose as soon as you remember, unless the next scheduled dose is close. Skipping and resuming your regular schedule is typically preferred over doubling up.

Do I need professional guidance to use retatrutide?
Professional guidance is strongly recommended. Retatrutide is potent, newer than most alternatives, and has less real-world safety data than older compounds in the same class.

Track your retatrutide ramp, calculate your reconstitution, and log every dose at dosevault.app.

Educational content only. This article does not diagnose, treat, cure, or prevent any condition. Consult a licensed healthcare professional before using any peptide.